Evidence map›Paper›PMID 27268034›Full record

ArticleBMC cancer2016

Time course decomposition of cell heterogeneity in TFEB signaling states reveals homeostatic mechanisms restricting the magnitude and duration of TFEB responses to mTOR activity modulation.

Paula Andrea Marin Zapata, Carsten Jörn Beese, Anja Jünger, Giovanni Dalmasso, Nathan Ryan Brady, Anne Hamacher-Brady

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Paula Andrea Marin ZapataLysosomal Systems Biology, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany.
Carsten Jörn BeeseLysosomal Systems Biology, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany.
Anja JüngerLysosomal Systems Biology, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany.
Giovanni DalmassoLysosomal Systems Biology, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany.
Nathan Ryan BradySystems Biology of Cell Death Mechanisms, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany. nbrady7@jhu.edu.
Anne Hamacher-BradyLysosomal Systems Biology, German Cancer Research Center (DKFZ) and BioQuant, University of Heidelberg, Heidelberg, Germany. abrady9@jhu.edu.
German Cancer Research Center · DEHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTFEB (transcription factor EB) regulates metabolic homeostasis through its activation of lysosomal biogenesis following its nuclear translocation. TFEB activity is inhibited by mTOR phosphorylation, which signals its cytoplasmic retention. To date, the temporal relationship between alterations to mTOR activity states and changes in TFEB subcellular localization and concentration has not been sufficiently addressed.

methodsmTOR was activated by renewed addition of fully-supplemented medium, or inhibited by Torin1 or nutrient deprivation. Single-cell TFEB protein levels and subcellular localization in HeLa and MCF7 cells were measured over a time course of 15 hours by multispectral imaging cytometry. To extract single-cell level information on heterogeneous TFEB activity phenotypes, we developed a framework for identification of TFEB activity subpopulations. Through unsupervised clustering, cells were classified according to their TFEB nuclear concentration, which corresponded with downstream lysosomal responses.

resultsBulk population results revealed that mTOR negatively regulates TFEB protein levels, concomitantly to the regulation of TFEB localization. Subpopulation analysis revealed maximal sensitivity of HeLa cells to mTOR activity stimulation, leading to inactivation of 100 % of the cell population within 0.5 hours, which contrasted with a lower sensitivity in MCF7 cells. Conversely, mTOR inhibition increased the fully active subpopulation only fractionally, and full activation of 100 % of the population required co-inhibition of mTOR and the proteasome. Importantly, mTOR inhibition activated TFEB for a limited duration of 1.5 hours, and thereafter the cell population was progressively re-inactivated, with distinct kinetics for Torin1 and nutrient deprivation treatments.

conclusionTFEB protein levels and subcellular localization are under control of a short-term rheostat, which is highly responsive to negative regulation by mTOR, but under conditions of mTOR inhibition, restricts TFEB activation in a manner dependent on the proteasome. We further identify a long-term, mTOR-independent homeostatic control negatively regulating TFEB upon prolonged mTOR inhibition. These findings are of relevance for developing strategies to target TFEB activity in disease treatment. Moreover, our quantitative approach to decipher phenotype heterogeneity in imaging datasets is of general interest, as shifts between subpopulations provide a quantitative description of single cell behaviour, indicating novel regulatory behaviors and revealing differences between cell types.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell NucleusCytoplasmFlow CytometryHeLa CellsHomeostasisHumansMCF-7 CellsMicroscopy, FluorescenceNeoplasmsPhosphorylationSignal TransductionSingle-Cell AnalysisTime FactorsTOR Serine-Threonine KinasesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsMTOR protein, humanTFEB protein, humanTOR Serine-Threonine KinasesAutophagyLysosomesMammalian target of rapamycin (mTOR)Multispectral imaging cytometryProteasomeSingle cellSubpopulation dynamicsSystems biologyTranscription Factor EB (TFEB)

Identifiers

PMID27268034
PMCPMC4896000
OpenAlexW2413006966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.